Afatinib
99%
- Product Code: 110630
CAS:
439081-18-2
Properties:
DMSO 97 mg/mL,Water 1 mg/mL,Ethanol 15 mg/mL
| Molecular Weight: | 485.94 g./mol | Molecular Formula: | C₂₄H₂₅ClFN₅O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD12407405 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Afatinib is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. It is particularly effective for patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. The drug works by irreversibly inhibiting the tyrosine kinase activity of EGFR, HER2, and HER4, thereby blocking the signaling pathways that promote cancer cell growth and survival. Afatinib is often prescribed as a first-line treatment for advanced or metastatic NSCLC with these mutations. It is available in tablet form and is taken orally, typically once daily. Common side effects include diarrhea, skin rash, and mouth sores, which are managed with supportive care. Regular monitoring and dose adjustments may be necessary to ensure optimal therapeutic outcomes and minimize adverse effects.
Product Specification:
| Test | Specification |
|---|---|
| Purity | 98.5-100 |
| Melting Point | 100-102 |
| Appearance | Off-white Powder |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿560.00 |
+
-
|
| 0.050 | 10-20 days | ฿880.00 |
+
-
|
| 0.250 | 10-20 days | ฿2,000.00 |
+
-
|
| 1.000 | 10-20 days | ฿5,990.00 |
+
-
|
| 5.000 | 10-20 days | ฿21,680.00 |
+
-
|
Afatinib
Afatinib is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. It is particularly effective for patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. The drug works by irreversibly inhibiting the tyrosine kinase activity of EGFR, HER2, and HER4, thereby blocking the signaling pathways that promote cancer cell growth and survival. Afatinib is often prescribed as a first-line treatment for advanced or metastatic NSCLC with these mutations. It is available in tablet form and is taken orally, typically once daily. Common side effects include diarrhea, skin rash, and mouth sores, which are managed with supportive care. Regular monitoring and dose adjustments may be necessary to ensure optimal therapeutic outcomes and minimize adverse effects.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :